Detail akcie RAPT Therap Rg online

Business Summary: RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Rapt Therapeutics Inc revenues was not reported. Net loss decreased 32% to $52.4M. Lower net loss reflects Research and development decrease of 42% to $30.8M (expense), Stock-based Compensation in R&D decrease of 23% to $5.6M (expense), Other (income) increase of 16% to $3.9M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$15.81 to -$1.94.